Evidence shows that targeting RAD51 contributes to overcome the radioresistance of some kinds of cancers [70,104,105], such as methotrexate inhibiting RAD51 expression and radiosensitizing human osteosarcoma cells [106]. The gene discussed is RAD51; the disease is cancer.